Scarica l'app Stockscreener
2.28
1.30%
-0.03
Dopo l'orario di chiusura:
2.28
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AYTU Giù?
Forum
Previsione
Frazionamento azionario
Aytu Biopharma Inc Borsa (AYTU) Ultime notizie
Conferencia de resultados del cuarto trimestre fiscal de 2026 de Aytu BioPharma (AYTU): crecimiento de EXXUA y perspectivas para el ejercicio fiscal 2027 - TradingKey
Teleconferência de Resultados do 4º Trimestre Fiscal de 2026 da Aytu BioPharma (AYTU): Crescimento do EXXUA e Perspectivas para o Ano Fiscal de 2027 - TradingKey
Aytu BioPharma, Inc. (AYTU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aytu BioPharma, Inc. Q4 2026 Earnings Call Summary - Yahoo Finance
AYTU|Aytu Biopharma Inc|Price:2.230|Chg%:+0.105 - TradingKey
Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EX - GuruFocus
Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ... - Yahoo Finance
AYTU Looks 147.8% Overvalued on GF Value™ - GuruFocus
Aytu BioPharma beats Q4 estimates on EXXUA launch momentum, shares rise 4% - Investing.com Nigeria
Is Aytu BioPharma Inc (AYTU) Worth the Investment After Q4 Resul - GuruFocus
AYTU: EXXUA prescriptions and revenue surged in Q4, driving positive adjusted EBITDA and cash stability - TradingView
Aytu BioPharma Narrows Fiscal 2026 Loss to $14.3 Million as EXXUA Debuts - Minichart
Aytu Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Aytu BioPharma tops Q4 2026 revenue forecast - Investing.com
AYTU: EXXUA momentum drove Q4 revenue growth and positive EBITDA, with FY27 set for further investment - TradingView
Aytu BioPharma beats Q4 estimates on EXXUA launch momentum, shares rise 4% By Investing.com - Investing.com South Africa
Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call - Benzinga
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Aytu Fiscal Q4 2026 Earnings: EXXUA Drives Revenue Growth - TradingKey
AYTU BIOPHARMA, INC FY 2026: Revenue $57.57M, EPS ($1.16) — 10-K Summary - TradingView
AYTU: EXXUA launch drove $6.6M in revenue, but overall sales fell 13% and net loss reached $14.3M - TradingView
New antidepressant adds revenue at Aytu BioPharma (NASDAQ: AYTU) as legacy drugs decline - Stock Titan
Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 - marketscreener.com
Aytu BioPharma reports FY2026 revenue $57.6M, Q4 revenue $16.1M and Adjusted EBITDA $0.5M - TradingView
Aytu BioPharma Reports $16.1 Million Q4 Revenue as EXXUA Reaches $3.9 Million - Quiver Quantitative
AYTU: Q4 revenue rose 6.4% on EXXUA's launch, while full year revenue declined amid portfolio shifts - TradingView
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results - Voice of Alexandria
EXXUA prescriptions jump as Aytu BioPharma (AYTU) posts Q4 and full-year results - Stock Titan
AYTU Looks 154.9% Overvalued on GF Value™ - GuruFocus
AYTU Q4'26 Earnings: EPS estimate is (0.29) USD - TradingView
Aytu Biopharma Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Aytu BioPharma Q4FY26 Results: Sales up 6.4% YoY to $16.1M - scanx.trade
Aytu BioPharma will share yearly results Sept. 22 - Stock Titan
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 - ACCESS Newswire
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sets FY26, Q4 Results Date - TradingView
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Turn A Profit? - simplywall.st
AYTU Q2 2026 Earnings: Loss Per Share Misses by 1.88% as Stock Holds UpDividend Cut Risk - vinanet.vn
AYTU | AYTU BioPharma, Inc. Common FinancialsRevenue Breakdown - Quiver Quantitative
Aytu (AYTU) Q2 2026 Earnings: EPS Misses Its Estimate; Closing Move: The Market Reaction Is Muted in the Current UpdatePerformance Review - vinanet.vn
Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake - Stock Titan
Aytu BioPharma (AYTU) Slips 1.7% to $2.36 as Biotech Volatility PersistsRisk Parity Rebalance - vinanet.vn
Aytu Biopharma Inc (AYTU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AYTU Q2 2026 Earnings: Narrow EPS Miss Slightly Wider Than Expected, Shares Rise 1.69%Earnings Expansion Phase - vinanet.vn
Aytu Biopharma Inc (AYTU) Stock News Today - TradingKey
Aytu BioPharma, Inc. (0A8M.L) valuation measures and financial statistics - Yahoo Finance Australia
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Aytu BioPharma (AYTU) Climbs 3.72% to $2.23 — Approaching Key ResistanceDynamic Hedging - careplusvn.com
Aytu BioScience Inc (0A8M) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Aytu Biopharma Inc (AYTU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aytu Biopharma Inc (AYTU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aytu BioPharma Market Sentiment - Benzinga España
Aytu Biopharma Inc (AYTU) Cash Flow - TradingKey
Aytu Biopharma Inc (AYTU) Balance Sheet - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.107|Chg%:+0.046 - TradingKey
AYTU|Aytu Biopharma Inc|Price:2.160| - TradingKey
Aytu Biopharma Inc (AYTU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aytu Biopharma Inc (AYTU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aytu Biopharma Inc (AYTU) Income Statement - TradingKey
AYTU Q2 2026 Earnings: EPS Misses Estimates by Nearly 2%, Stock Holds SteadySaaS Earnings Trends - careplusvn.com
Aytu BioPharma, Inc. Revenue Breakdown – NASDAQ:AYTU - TradingView
AYTU Q2 2026 Earnings: EPS Slightly Misses Estimates with Minimal SurpriseEarnings Quality Score - careplusvn.com
AYTU Q2 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterEstimate Revision Count - careplusvn.com
Aytu BioPharma (AYTU) Edges Higher as Stock Tests Key ResistanceFear Greed Index - dars.gov.et
AYTU Q2 2026 Earnings: EPS Misses Estimates Amid No Revenue; Stock Edges HigherCapex Guidance - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Consensus, Stock Falls SlightlyRevenue Guidance Update - vinanet.vn
AYTU Q2 2026 Earnings: EPS Misses Estimates, Stock DeclinesEarnings Whisper Number - careplusvn.com
New Strong Sell Stocks for July 16th - Yahoo Finance
AYTU Q2 2026 Earnings: EPS Misses Estimates, Shares Edge HigherSegment Revenue Breakdown - dars.gov.et
0.18%
0.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):